A First Human Dose Trial Investigating the Safety, Tolerability and Pharmacokinetics of Single Doses of Oral NNC0113-2023 in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 21 Jan 2019
At a glance
- Drugs NNC0113-2023 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors Novo Nordisk
- 11 Jan 2019 Status changed from active, no longer recruiting to completed.
- 06 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 04 Sep 2018 Status changed from not yet recruiting to recruiting.